The abstract is read at the publisher; the summary is JClub's.
The ACMG/CAP technical standard for prenatal maternal plasma cfDNA screening establishes uniform laboratory validation, monitoring, and reporting practices for chromosome abnormalities.
- Why it matters: Laboratories face challenges implementing and validating prenatal cfDNA tests, and consistent quality is needed for a screening approach recommended as first-tier for common fetal aneuploidies.
- What they did: The work group provides guidance for technical standards covering validation methods, ongoing quality/performance monitoring, and interpretation and reporting for maternal plasma cfDNA screening.
- The result: The standard functions as a resource to help clinical laboratories implement prenatal cfDNA screening reliably, supporting detection of trisomies 13, 18, and 21, sex chromosome aneuploidy, and recurrent segmental aneuploidies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.